A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

* Men between 45 and 80 years age * Participants with low serum testosterone concentrations (\< 300 ng/dL) who exhibit at least one sign or symptom of hypogonadism and have evidence of cardiovascular (CV) disease or are at an increased risk for CV disease.

* Participants with congenital or acquired hypogonadism for whom long-term therapy with placebo would not be medically appropriate * Participants with prostate specific antigen (PSA) \> 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors) * Participants who have been treated with testosterone in the past 6 months and for whom testosterone therapy is contraindicated * Confirmed testosterone \< 100 ng/dL * Body Mass Index (BMI) \> 50 * Hemoglobin A1c (HbA1C) \> 11% * Hematocrit (Hct) \> 50% * Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min * History of deep vein thrombosis or pulmonary embolism or prostate cancer or heart failure (Class III and IV).